ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells

Melanoma Research

Volumn 15, Issue 1, 2005, Pages 21-28

  Gordon Thomson, Clare ^a   Jones, Jackson ^a   Mason, Rebecca S ^b   Moore, G Philip M ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cell growth; ErbB receptors; HRG ; HRG ; Melanocytes; Melanoma; TGF ; Wound closure

Indexed keywords

ANTISERUM; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HEREGULIN BETA1; NEU DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BIOASSAY; CANCER CELL CULTURE; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MELJG; CELL STRAIN MM96L; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; RECEPTOR BINDING; RECEPTOR UPREGULATION; SCRATCH WOUND CLOSURE ASSAY; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; WOUND CLOSURE;

CELL MOVEMENT; CELL PROLIFERATION; HUMANS; IMMUNOPRECIPITATION; MELANOCYTES; MELANOMA; NEUREGULIN-1; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; WOUND HEALING;

EID: 14844354802     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200502000-00005     Document Type: Article

References (40)

1. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-1655.
2. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett 1999; 447:227-231,
3. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network. Receptor heterodimerisation in development and cancer. EMBO J 2000; 19:3159-3167.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
5. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, et al. Enhanced tumorigenic behaviour of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996; 271:25 639-25 645.
6. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77:25-79.
7. Gordon-Thomson C, Mason RS, Moore GPM. Regulation of epidermal growth factor receptor expression in human melanocytes. Exp Dermatol 2001; 10:321-328.
8. de Wit PEJ, Moretti S, Koenders PG, Weterman MAJ, van Muijen GNP, Gianotti B, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992; 99: 168-173.
9. Marquardt H, Todaro GJ. Human transforming growth factor α: production by a melanoma cell line, purification and initial characterization. J Biol Chem 1982; 257:5220-5225.
10. Coffey RJ, Derynck R, Wilcox JN, Bringman TS, Goustin AS, Mo HL, et al. Production and auto-induction of TGFα in human keratinocytes. Nature 1987; 328:817-820.
11. Mattel S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994; 56:853-857.
12. Ellem KA, Cullinan M, Baumann KC, Dunstan A. UVR induction of TGFα: a possible autocrine mechanism for the epidermal melanocyte response and for promotion of epidermal carcinogenesis. Carcinogenesis 1988; 9:797-801.
13. Krasagakis K, Garbe C, Zouboulis ChC, Orfanos CE. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 1995; 139:169-182.
14. Pittelkow MR, Shipley GD. Serum-free culture of normal human melanocytes: growth kinetics and growth factor requirements. J Cell Physiol 1989; 140:565-576.
15. Sutton R, Gordon-Thomson C, Cree IA, Mason RS, Moore GPM. Tyr-TGFα transgenic mice develop ocular melanocytic lesions. Melanoma Res 2002; 12:435-439.
16. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterisation of ErbB3, a third member of the ErbB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci 1989; 86:9193-9197.
17. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995; 60:129-136.
18. Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Biggotti A, Trizio D, et al. Expression of gp185HER-2 in cutaneous melanoma: implications for experimental immunotherapeutics. Int J Cancer 1994; 56:541-546.
19. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res 2000; 10:401-411.
20. Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR, et al. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 1997; 17:1319-1330.
21. De Potter IY, Poumay Y, Squillace KA, Pittelkow MR. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 2001; 271:315-328.
22. Pope JH, Morrison L, Moss DJ, Parsons PG, Regius Mary Sister. Human malignant melanoma cell lines. Pathology 1979; 11:191-195.
23. McLeod SC, Smith C, Mason RS. Stimulation of tyrosinase in human melanocytes by pro-opiocortin-derived peptides. Endocrinology 1995; 146:439-447.
24. Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, et al. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 2002; 21:8442-8452.
25. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities. J Biol Chem 1996; 271:6071-6676.
26. Cha D, O'Brien P, O'Toole EA, Woodley DT, Hudson LG. Enhanced modulation of keratinocyte motility by transforming growth factor-α (TGF-α) relative to epidermal growth factor (EGF). J Invest Dermatol 1996; 106:590-597.
27. Vecchi M, Rudolph-Owen LA, Brown CL, Dempsey PJ, Carpenter G. Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the erbB-4 receptor and amphiregulin. J Biol Chem 1998; 273:20589-20595.
28. Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, et al. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 1997; 272:26761-26768.
29. Stove C, Stove V, Derycke L, Van Marck V, Mareel M, Bracke, M. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of dysregulation. J Invest Dermatol 2003; 121:802-812.
30. Ni CY, Yuan H, Carpenter G. Role of the ErbB-4 carboxyterminus in gamma-secretase cleavage. J Biol Chem 2002; 278:4561-4565.
31. Juntilla TT, Sundvall M, Maatta JA, Elenius K. ErbB4 and its isoforms. Selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000; 10:304-310.
32. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003; 284:66-77.
33. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Nuclear expression of the erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000; 60:1483-1487.
34. Gordon PR, Mansur CP, Gilchrest BA. Regulation of human melanocyte growth, dendricity, and melanisation by keratinocyte derived factors. J Invest Dermatol 1989; 92:565-572.
35. Valyi-Nagy IT, Hirka G, Jensen PJ, Shih I-M, Juhasz I, Herlyn M. Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest 1993; 69:152-159.
36. Ramon y Cajal S, Suster S, Halaban R, Filvaroff E, Dotto GP. Induction of different morphological features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. Am J Pathol 1991; 138:349-358.
37. Morelli JG, Yohn JJ, Zekman T, Norris DA. Melanocyte movement in vitro: role of matrix proteins and integrin receptors. J Invest Dermatol 1993; 101: 605-608.
38. Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115: 337-344.
39. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. Expression of the c-erbB-4/ HER4 protein and mRNA in normal human fetal and adult tissues in a survey of nine solid tumour types. J Pathol 1998; 185:236-245.
40. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, et al. Coexpression of erbB2 and erbB3 proteins contitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269:14661-14665.